目的观察对比玻璃体腔注射雷珠单抗治疗糖尿病黄斑水肿（DME）与视网膜静脉阻塞性黄斑水肿（RVO-ME）的疗效。方法2013年5月至2014年12月在安徽医科大学第一附属医院眼科门诊确诊为DME 及RVO-ME的患者，共26例（33只眼），其中DME 17只眼，RVO-ME 16只眼。患眼接受玻璃体腔注射雷珠单抗（0．5 mg／0．05 ml）治疗，治疗前和治疗后1 d、2周、4周定期门诊回访观察最佳矫正视力（BCVA）及中央黄斑厚度（CST）。比较雷珠单抗治疗两组治疗前和治疗后的BCVA及CST改变情况。结果 DME组与RVO-ME组治疗后1 d、2周、4周的BCVA均较治疗前明显提高，差异均有统计学意义（P ＜0．05）。DME组与RVO-ME组治疗后4周的CST均较治疗前明显改善，差异均有统计学意义（P ＜0．05）。DME组与RVO-ME组之间在BCVA及CST方面比较，差异均无统计学意义（P ＞0．05）。结论玻璃体腔注射雷珠单抗治疗DME及RVO-ME均可减轻黄斑水肿和改善视力，两者治疗效果无明显差异。%Objective To observe and compare the effects of the ranibizumab intravitreal injection on DME and RVO-ME. Methods This study investigated 26 patients (33 eyes)with 17 either DME (n = 17)RVO-ME (n = 16). All patients received ranibizumab 0. 05ml intravitreal injection. The follow-up examinations were at 1 day,2 weeks and 4 weeks after the treatment. The best corrected visual acuity (BCVA)and central macular thickness (CST)were observed and compared between DME patients and RVO-ME patients before and after injection. Results The BCVA significantly improved at 1 day,2 weeks and 4 weeks after injection in both groups in comparison with that before injection (P <0. 05). CST also significantly reduced in both groups after treatment (P < 0. 05). There was no difference between the two groups of the patients in BCVA and CST after treatment (P > 0. 05). Conclusion Ranibizumab intravitreal injection can reduce macular edema and improve the visual activity in patients with DME or RVO-ME. The treatment effect was simi-lar for DME and RVO-ME.
展开▼
